Facet Biotech and Bristol-Myers Squibb Report Promising Phase I/II Interim Data for Elotuzumab
- Details
- Category: Bristol-Myers Squibb
Facet Biotech Corporation (Nasdaq: FACT) and Bristol-Myers Squibb Company (NYSE: BMY) announced that potentially promising data from a Phase I/II study of elotuzumab, an investigational humanized antibody being studied for the treatment of relapsed multiple myeloma (MM), were presented at the American Society of Hematology (ASH) 2009 Annual Meeting in New Orleans.
Novo Nordisk starts phase 1 trial with oral insulin analogue
- Details
- Category: Novo Nordisk
Novo Nordisk has initiated its first phase 1 clinical trial with an oral insulin analogue (NN1952). This milestone releases a USD 2 million payment to Merrion Pharmaceuticals plc, whose GIPET® technology is used in the formulation of NN1952.
Sanofi-aventis enters into an Exclusive Global Licensing Agreement with The Rockefeller University
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced an exclusive global licensing agreement with The Rockefeller University (New York, NY) concerning a novel monoclonal antibody, targeting certain specific forms of the Amyloid Beta parenchymal plaque for the treatment of Alzheimer's disease.
New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists
- Details
- Category: Amgen
Each year, hundreds of undergraduate students from across the United States (U.S.) and Europe participate in the Amgen Scholars Program to gain hands-on laboratory experience under renowned faculty members at the world's leading universities. Now, the Amgen Scholars - past, present and future - will have exclusive access to the online Amgen Scholars Community.
AstraZeneca and Targacept Form Global Collaboration and Licence Agreement
- Details
- Category: AstraZeneca
AstraZeneca and Targacept, Inc. announced a collaboration and licence agreement for the global development and commercialisation of TC-5214, Targacept's late-stage investigational product for major depressive disorder (MDD). TC-5214, which recently completed a phase IIb clinical trial, is a nicotinic channel blocker that is thought to treat depression by modulating the activity of various neuronal nicotinic receptor (NNR) subtypes.
Resource Guide About Key Issues Facing the Pharmaceutical Industry
- Details
- Category: Eli Lilly and Company
The educational resource, "The Value of Medicine, Improving Health... Improving Life," created by Lilly USA (NYSE: LLY), is now available for download. The booklet supports Lilly's commitment to providing "Answers That Matter" and encourages an open dialogue with patients, providers, payers and the public about pharmaceutical industry practices.
GSK's Arepanrix⢠H1N1 pandemic vaccine prequalified by the World Health Organization
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) announced that the World Health Organization (WHO) has awarded prequalification for global use of Arepanrix™, GSK's adjuvanted H1N1 pandemic vaccine manufactured in Canada. This is the first prequalification for an H1N1 pandemic vaccine, and is a key step in ensuring the vaccine can be distributed to developing countries.
More Pharma News ...
- Merck KGaA Receives Refuse to File Letter from FDA on Cladribine Tablets New Drug Application
- Pfizer And Protalix Enter Into Agreement To Develop And Commercialize Gaucher's Disease Treatment
- "Positive Charge" to Help Address Barriers and Provide Support to People Living with HIV/AIDS
- Bayer Starts Phase III Trial with Florbetaben
- Bayer starts pivotal Phase III trial with Florbetaben
- Novartis gains rights to two oral targeted investigational therapies
- Lundbeck initiates clinical phase II trials with Lu AE58054